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Secondary Variants in Individuals Undergoing Exome
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Jennifer J. Johnston,1,7 Wendy S. Rubinstein,1,2,3,7,8 Flavia M. Facio,1 David Ng,1 Larry N. Singh,1
Jamie K. Teer,1,4 James C. Mullikin,1,4,5,6 and Leslie G. Biesecker1,4,*
Genome- and exome-sequencing costs are continuing to fall, and many individuals are undergoing these assessments as research partic-
ipants and patients. The issue of secondary (so-called incidental) findings in exome analysis is controversial, and data are needed on
methods of detection and their frequency. We piloted secondary variant detection by analyzing exomes for mutations in cancer-suscep-
tibility syndromes in subjects ascertained for atherosclerosis phenotypes. We performed exome sequencing on 572 ClinSeq participants,
and in 37 genes, we interpreted variants that cause high-penetrance cancer syndromes by using an algorithm that filtered results on the
basis of mutation type, quality, and frequency and that filteredmutation-database entries on the basis of defined categories of causation.
We identified 454 sequence variants that differed from the human reference. Exclusions were made on the basis of sequence quality (26
variants) and high frequency in the cohort (77 variants) or dbSNP (17 variants), leaving 334 variants of potential clinical importance.
These were further filtered on the basis of curation of literature reports. Seven participants, four of whom were of Ashkenazi Jewish
descent and three of whom did not meet family-history-based referral criteria, had deleterious BRCA1 or BRCA2 mutations. One
participant had a deleterious SDHCmutation, which causes paragangliomas. Exome sequencing, coupled with multidisciplinary inter-
pretation, detected clinically important mutations in cancer-susceptibility genes; four of such mutations were in individuals without
a significant family history of disease.We conclude that secondary variants of high clinical importance will be detected at an appreciable
frequency in exomes, and we suggest that priority be given to the development of more efficient modes of interpretation with trials in
larger patient groups.Introduction
High-throughput sequencing is effective for elucidating
the cause of heritable disorders1 and for interrogating
many genes in high-risk individuals.2 The number of
research subjects undergoing exome or genome se-
quencing is rapidly increasing. Apart from the identifica-
tion of the mutation causing the disorder for which the
sequencing was performed (i.e., the primary variant),
genome and exome sequencing have the potential to iden-
tify other clinically important results (i.e., secondary or so-
called incidental variants). The number of clinically impor-
tant secondary variants in human genomes is substantial.
Each genome in the 1000 Genomes Project has 50–100
variants in disease-associated genes,3 and a screen4 of 104
exomes for 448 severe recessive diseases found an average
carrier burden of 2.8 variants per person. Recommended
interventions for highly penetrant conditions might
include prophylactic cancer surgery and screening,5 im-
plantation of a cardioverter defibrillator,6 and pharmaco-
genomic7 and reproductive decision making.8
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The Abe sought, and if they are sought or accidentally encoun-
tered, whether and how these variants should be returned
to patients or research subjects.9–11 To shed light on this
controversy, we set out to develop approaches to the anal-
ysis and return of whole-exome sequencing (WES) results
for secondary (or so-called incidental) variants in genes
associated with high-penetrance cancer-susceptibility
syndromes in a cohort not ascertained for these condi-
tions. We piloted these approaches on 572 ClinSeq12
participants and report the yield, utility, and limitations
of this strategy. Finally, we discuss the implications of
these findings for researchers generating these kinds of
data and considering whether—and how—to return such
results to study participants.Subjects and Methods
Study Participants
ClinSeq participants were 45–65 years of age and gave consent
for genome and exome sequencing and the return of results.12
They were selected for a range of atherosclerosis phenotypes, but
not for personal or family histories of cancer. Family history,
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Table 1. The 37 Cancer-Associated Genes Analyzed in this Study and a Summary of Variants Identified in Each Gene by Pathogenicity Score
Gene
RefSeq Accession
Number Disease Associations MIM Number
Total
Variants
Pathogenicity Scorea
0 1 2 3 4 5
APC NG_008481.4 familial adenomatous polyposis 175100, 611731,
and 135290
45 1 6  38  
BMPR1A NG_009362.1 familial juvenile polyposis 174900 and 601299 4  1  3  
BRCA1 NG_005905.2 hereditary breast and
ovarian cancer
113705 40 2 13 3 20  2
BRCA2 NG_012772.1 hereditary breast and
ovarian cancer
600185 52 1 11 9 28  3
CDC73 (HPRT2) NG_012691.1 familial hyperparathyroidism
and hereditary
hyperparathyroidism-jaw
tumor syndrome
145000 and 145001 1    1  
CDH1 NG_008021.1 hereditary diffuse gastric cancer 137215 and 192090 6  1  5  
CDKN2A NG_007485.1 hereditary multiple melanoma 155601, 155755, 600160,
and 606719
9  2  7  
FH NG_012338.1 hereditary renal cell carcinoma
with multiple cutaneous and
uterine leiomyomas
605839, 136850,
and 150800
5    5  
FLCN NG_008001.1 Birt-Hogg-Dube´ syndrome 135150 and 607273 10  2  8  
KIT NG_007456.1 gastrointestinal stromal tumor 606764 and 164920 11 1 1  9  
MEN1 NG_008929.1 multiple endocrine
neoplasia type 1
131100 6  2  4  
MET NG_008996.1 hereditary papillary renal
cell carcinoma
605074 and 164860 30 6 4  20  
MLH1 NG_007109.1 hereditary nonpolyposis colon
cancer (Lynch syndrome)
609310, 276300, 608089,
158320, 120436,
and 120435
14  6  8  
MSH2 NG_007110.1 hereditary nonpolyposis colon
cancer (Lynch syndrome)
276300, 608089, 158320,
20435, and 609309
15  3  12  
MSH6 NG_007111.1 hereditary nonpolyposis colon
cancer (Lynch syndrome)
276300, 608089, 120435,
and 600678
15 1 2  12  
MUTYH NG_008189.1 MYH-associated polyposis 608456 and 604933 20 1 5  10 2 2
NF1 NG_009018.1 neurofibromatosis type 1 162200, 162210, and 193520 14 1 2  11  
NF2 NG_009057.1 neurofibromatosis type 2 101000 and 607379 1    1  
PDGFRA NG_009250.1 gastrointestinal stromal tumor 606764 and 173490 15 2 2  11  
PMS2 NG_008466.1 hereditary nonpolyposis colon
cancer (Lynch syndrome)
276300, 608089, 120435,
and 600259
29 4 12  13  
PRKAR1A NG_007093.2 Carney complex type 1 160980, 188830, and 610489 0      
PTCH1 NG_007664.1 nevoid basal cell
carcinoma syndrome
109400 and 601309 20  4  16  
PTEN NG_007466.1 Cowden disease 158350 and 601728 1    1  
RB1 NG_009009.1 hereditary retinoblastoma 180200 4 1   3  
RET NG_007489.1 multiple endocrine neoplasia
types 2A and 2B and familial
medullary thyroid cancer
171400, 155240, 162300,
and 164761
15  4 1 10  
SDHAF2 NG_023393.1 hereditary paraganglioma 601650 and 613019 2    2  
SDHB NG_012340.1 hereditary paraganglioma 115310 and 185470 4  1  3  
SDHC NG_012767.1 hereditary paraganglioma 605373 and 602413 9 4 2  2  1
SDHD NG_012337.1 hereditary paraganglioma 168000 and 602690 3  1  2  
SMAD4 NG_013013.1 familial juvenile polyposis 174900, 175050, and 600993 2    2  
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Table 1. Continued
Gene
RefSeq Accession
Number Disease Associations MIM Number
Total
Variants
Pathogenicity Scorea
0 1 2 3 4 5
SMARCB1 NG_009303.1 schwannomatosis 162091 and 601607 1    1  
STK11 NG_007460.1 Peutz-Jeghers syndrome 175200 and 602216 0      
TP53 NG_017013.1 Li-Fraumeni syndrome 151623, 191170, and 202300 2  1  1  
TSC1 NG_012386.1 tuberous sclerosis complex 1 191100 and 605284 17 1 2 4 10  
TSC2 NG_005895.1 tuberous sclerosis complex 2 191092 and 613254 28 1 4 11 12  
VHL NG_008212.2 von Hippel-Lindau syndrome 193300 and 608537 1    1  
WT1 NG_009272.1 familial Wilms tumor 1 607102 and 194070 1    1  
aPathogenicity scores were determined as described in the Subjects and Methods. In brief, a score of 0 indicates poor sequence quality, 1 indicates benign, 2
indicates a high chance of the variant being benign, 3 indicates a wide range of probability that the variant is benign, 4 indicates a high chance of the variant
being pathogenic, and 5 indicates pathogenicity. Detailed data for individual variants are reported in Table S1.The institutional review board (IRB) at the National Human
Genome Research Institute reviewed and approved this study,
and all subjects provided written informed consent.
Gene List
We developed a list (Table 1) comprising 27 cancer syndromes
caused by mutations in 37 genes. The list was based on the
‘‘Concise handbook of familial cancer susceptibility syndromes—
second edition’’ (2008).13 We added SDHAF2 (MIM 613019),
implicated in paragangliomas 2 (MIM 601650), because that was
positionally cloned after this chapter was written. The gene list
was frozen as of the end of 2010. Seventeen primarily pediatric
syndromes were excluded because these syndromes were unlikely
to be clinically unrecognized in subjects older than 45 years. This
curated list comprises mainly autosomal-dominant, high-pene-
trance syndromes except for familial adenomatous polyposis 2
(MIM 608456), an autosomal-recessive disorder, because it is
similar in penetrance to some dominant, high-penetrance cancer
syndromes.13
Next-Generation Sequencing and Variant Analysis
DNA was isolated from whole blood via the salting-out method
(Qiagen, Valencia, CA). Solution-hybridization exome capture
was performed with the SureSelect All Exon System (Agilent Tech-
nologies, Santa Clara, CA). The manufacturer’s protocol version
1.0, compatible with Illumina paired-end sequencing, was used.
Flow-cell preparation and sequencing of 101 bp paired-end reads
were performed for the GAIIx sequencer14 (Illumina, San Diego,
CA). Image analyses and base calling were performed as
described.14 Reads were aligned to hg18 (NCBI build 36) with
ELAND (Illumina). Uniquely aligned reads were grouped into
~100 kb intervals, and unaligned reads were binned with their
paired-end mates. Binned reads were aligned to their genomic
sequence bin with cross_match and the use of parameters –min-
score 21 and –masklevel 0. Typically, one or two 101 bp paired-
end flow-cell lanes, or 4–8 Gb of sequence, were sufficient for
the generation of R85% coverage of the targeted exome with
high-quality variant detection (reported as a genotype at every
callable position). Genotypes were called at high-quality sequence
bases (Phred-like RQ20) with Most Probable Genotype14 (MPG).
Filters were applied with the VarSifter Next-Gen variation analysis
software.15The AOur goal was to identify variations highly likely to be causative
and to receive few false positives; therefore, sensitivity was
sacrificed. We analyzed nonsense, frameshift, splice-site, and non-
synonymous variants in 37 cancer genes in 572 ClinSeq partici-
pants. Variants were filtered (Figure 1) on the basis of quality
and frequency. Quality filters included a MPG score R10 and an
MPG/read count ratio of >0.5. The most common of the
syndromes analyzed was hereditary breast and ovarian cancer
(HBOC, which includes BROVCA1 [MIM 604370] and BROVC2
[MIM 612555]), which had a frequency of ~1/500 for BRCA1
(MIM 113075) and BRCA2 (MIM 600185) combined.16 We
reasoned that an allele frequency of >0.5% in ClinSeq was appro-
priate for the exclusion of pathogenicity and that a SNP with
a minor allele frequency of >0.015 (dbSNP17 build 132, minimum
120 chromosomes) was unlikely to cause a highly penetrant, rare,
dominant disorder. Variants were graded from class 1 (almost
certainly benign) to class 5 (definitely pathogenic) with amodified
version of an established scale18. The modified classification
scheme presented in Table 2 relies on qualitative rather than quan-
titative assessments of variant causation. Adequate data do not
exist for the majority of variants to allow for quantitative assess-
ments. Therefore, we modified the original scale. Variants that
failed quality filters were assigned to class 0, and variants that
were excluded as pathogenic on the basis of frequency data were
assigned to class 1. For all other variants, the Human Gene Muta-
tion Database (HGMD19) and locus-specific databases (LSDBs20,21)
were consulted, and variants were assigned to pathogenicity
classes according to the guidelines presented in Table 2. Missense
variants or in frame indels not listed in HGMD or the consulted
LSDBs (these variants are hereafter referred to as novel variants)
were assigned to class 3. For novel nonsense, frameshift, and
splice-site variants, the characteristics of the gene and the variant,
as well as participant family history, were considered. When
HGMD and/or an LSDB reported a variant as pathogenic, we re-
viewed relevant citations to determine whether the variant should
be assigned to class 5. When the relevant citations supported
causation, we analyzed family-history data. For missense alter-
ations or in frame insertions/deletions, a single report was insuffi-
cient for the assignment of a variant to class 5. Variants not
reported as pathogenic by HGMD and/or an LSDB were defined
as variants of unknown significance (VUS). The VUSs were as-
signed to class 2 (highly likely to be benign), 4 (highly likely tomerican Journal of Human Genetics 91, 97–108, July 13, 2012 99
Figure 1. Filtering Criteria Used for Coding-Variant Interpre-
tation
Variants were filtered for quality with MPG scores and coverage,
frequency in ClinSeq and minor allele frequency in dbSNP, and
data present in the Human Gene Mutation Database (HGMD)
and locus specific databases (LSDBs) for each gene when available.
Variants were determined to be benign, pathogenic, or of
unknown significance (VUSs).be pathogenic), or 3 (a wide range from probably benign to
possibly pathogenic). An initial data freeze was analyzed at 258
exomes. For the 258 exome dataset, relevant citations from
HGMD and LSDBs were reviewed for all VUSs when they were
being assigned to pathogenicity classes. It was determined that
when HGMD or an LSDB did not identify a variant as pathogenic,
a literature review did not result in any variant being assigned to
class 5. For the 572 exome dataset, information available in
HGMD and LSDBs was analyzed, but the primary literature was
not reviewed for VUSs. Variants were assigned to class 2 if they
had been reported multiple times as benign or if multiple pieces
of evidence were presented against causation. Evidence against
causation included presence in controls, co-occurrence with
a known pathogenic mutation, and/or normal functional data.
Class 4 was assigned when multiple primary reports defined the
variant as pathogenic and evidence against causation was not pre-
sented. All other variants were assigned to class 3. Variants were
scored by individual investigators and then reviewed by all
authors. Probandswith BRCA1 or BRCA2 class 5 variants were eval-
uated with BRCAPRO (CancerGene package version 5.1, South-
western Medical Center at Dallas) and U.S. Preventive Services
Task Force Guidelines22 (applicable only to unaffected women).
The interpretations of individual variants, summarized in Table
S1, available online, were submitted to ClinVar to be assigned
a permanent accession. ClinVar is a new, centralized open-access100 The American Journal of Human Genetics 91, 97–108, July 13, 20database maintained by the National Institutes of Health National
Center for Biotechnology Information (NCBI), which collects
sequence-level and structural variant information, associated
phenotypic data, and clinical assertions from numerous clinical
laboratories and locus-specific databases. Although the ClinVar
resource is under construction, data have been collected from
several sources and are currently viewable through other active
NCBI resources, such as Variation Viewer. We are pleased to have
been the first to request ClinVar accessions before publication.
Return of Results
All class 5 variants predicted to cause an autosomal-dominant
cancer syndrome were confirmed in our Clinical Laboratory
Improvement Amendments (CLIA)-certified laboratory. The clinical
test results were provided to the participants by a clinical geneti-
cist. Participants with BRCA1 and BRCA2 variants were advised
on cancer prevention and surveillance guidelines developed by
the National Comprehensive Cancer Network (NCCN) and were
referred to community clinical resources for ongoing surveillance.
The participant with the SDHC (MIM 602413) variant was coun-
seled regarding the paragangliomas 3 phenotype (MIM 605373)
and its management according to published guidelines.23 Partici-
pants were encouraged to share their genetic results with their
families. Participants with at-risk relatives were counseled to
have those relatives receive mutation-specific clinical testing
through a clinician and an approved clinical testing laboratory.
Results containingmonoallelicMUTYH (MIM 604933) class 5 vari-
ants implicated in recessive familial adenomatous polyposis 2
were not returned to participants as part of this study but will be
validated and returned at a later time with other heterozygous-
carrier results for disorders inherited in a recessive pattern.Results
Participant Demographics
The dataset included 572 participants, of whom 92.2%
were white and 97.7%were not of Hispanic or Latino back-
ground. Seventeen percent of the study population was of
Ashkenazi ancestry. The median age was 58 years, and
46.5% were female and 53.5% were male.
Sequence Data
For the 572 exomes, 44.5 billion reads were generated,
resulting in 3.84 trillion bp of sequence and 1,921,814
variants. Copy-number variants and indels greater than
10 bp were not assessed, which is a limitation of exome
sequencing. A total of 181,736 variants were nonsynony-
mous, frameshift, nonsense, or splicing. The targeted
coding sequences of the 37 genes comprised 101,235 bp.
We achieved an overall coverage of 91.2%, and the per-
gene coverage was between 22.3% (for STK11 [MIM
602216]) and 100% (for SDHD and SMAD4 [MIM 602690
and 600993, respectively]) (Figure 2). Narrowing the results
to the 37 cancer genes identified 454 distinct potential
nonsynonymous, frameshift, nonsense, or splice variants.
Note that we counted variants once irrespective of whether
they were present in one or more individuals. One variant
was nonreference in all 572 participants and was excluded.
An indel at the 30 end ofMLH1 (MIM 120436) did not alter12
Table 2. Sequence-Variant Pathogenicity Categorization
Variants Not in Database Pathogenic Variants VUSs Benign Variants
Missense
Mutation
Nonsense,
Frameshift, and
Splice Mutations Missense Mutation
Nonsense, Frameshift,
and Splice Mutations Any Mutation Any Mutation
Class 5 consistent family
historya and loss-of-
function mutations
known to cause disease
multiple primary
reports as pathogenic
and no evidence
against causation
multiple or single
primary report as
pathogenic and no
evidence against
causation
Class 4 equivocal family
historya and loss-of-
function mutations
known to cause disease
multiple primary
reports as pathogenic
and evidence against
causation or a single
primary report as
pathogenic with
supporting evidence
of causation
multiple primary
reports as pathogenic
and a single piece
of evidence
against causation
multiple primary
reports as pathogenic
Class 3 all novel
missense
inconsistent family
historya or loss-of-
function mutations not
known to cause disease
single primary report
as pathogenic and no
supporting evidence
of causation
multiple primary
reports as pathogenic
and multiple pieces
of evidence against
causation or a single
primary report as
pathogenic and a single
piece of evidence
against causation
primary reports as a VUS a single report as
benign or primary
reports as pathogenic
Class 2 single primary report
as pathogenic and
multiple pieces of
evidence against
causation
single primary report
as pathogenic with
multiple evidence
against causation
multiple pieces of
evidence against
causation
multiple primary
reports as benign and
no supporting evidence
of causation or a single
primary report as
benign and multiple
pieces of evidence
against causation
Variants that passed quality and frequency filters were assigned to pathogenicity classes on the basis of data available in the Human Gene Mutation Database
(HGMD), locus specific databases (LSDBs), and family history. Variants that did not pass quality filters were defined as class 0, variants that did not pass frequency
filters were defined as class 1, and all other variants were assessed according to the criteria presented in the table. Evidence of causation can include but is not
limited to published segregation data, presence in controls, functional data, co-occurrence with a known pathogenic mutation, and participant family history.
The following abbreviation is used: VUSs, variants of unknown significance.
aParticipant family history that is compared to the reported phenotype and penetrance for loss-of-function mutations in gene.the predicted protein sequence and was excluded. Two
single-base variants were a single 2 bp indel and were
combined. This left a total of 451 variants (Table S1).
Variant Filtering and Classification
The 451 variants were filtered for quality (n ¼ 26, class 0),
leaving 425. Ninety-four variants were defined as class 1
on the basis of ClinSeq frequency (n ¼ 77) or dbSNP
frequency (n ¼ 17), leaving 331 (Figure 3). Of these 331
variants (classes 2–5), 186 were not listed in HGMD or
the consulted LSDBs and were considered novel. All novel
missense and single-amino-acid-deletion variants as well
as alterations in non-HGMD transcripts were defined as
class 3 (n ¼ 186). Variants included in HGMD or the
LSDBs, but not listed as pathogenic (n¼ 77), were classified
on the basis of information available in the databases.
Consideration was given to primary reports of pathoge-
nicity as well as factors including but not limited to pres-
ence in controls and functional data. These 77 variants
were defined as class 2 (n ¼ 16) or class 3 (n ¼ 61). The re-
maining 68 variants were listed as pathogenic in eitherThe AHGMD (n ¼ 59), the LSDBs (n ¼ 4), or both (n ¼ 5).
When variants were listed as pathogenic in HGMD or
LSDBs, relevant literature was reviewed. In cases where
the literature suggested that a variant was likely to be path-
ogenic, family-history data were reviewed. Of these 68
variants, 5 were described as pathogenic for diseases other
than cancer-susceptibility syndromes, leaving 63 variants
for assessment. Fifty-three of these variants were defined
as class 2 (n¼ 12) or class 3 (n¼ 41) on the basis of the liter-
ature review and/or participant family history, leaving ten
variants.
These ten variants were assigned to classes 4 or 5 and
included variants in MUTYH (class 4, n ¼ 2; class 5,
n ¼ 2), BRCA1 (class 5, n ¼ 2), BRCA2, (class 5, n ¼ 3),
and SDHC (class 5, n ¼ 1). High-penetrance colon cancer
is associated with biallelic MUTYH mutations; all variants
identified in MUTYH were monoalleleic. A variant in
SDHC (RefSeq NM_003001.3), c.43C>T (p.Arg15*) (class
5), was identified in a single proband without a personal
or family history of cancer. Mutations in SDHC predispose
to head and neck paragangliomas.merican Journal of Human Genetics 91, 97–108, July 13, 2012 101
Figure 2. Box and Whisker Plots Showing Base Coverage for 37 Cancer-Associated Genes across a Cohort of 572 Probands
The MIM numbers for these genes are listed in Table 1.The five remaining class 5 variants found among seven
participants were in BRCA1 (n ¼ 2) or BRCA2 (n ¼ 3)
(Table 3). One participant was heterozygous for BRCA1
(RefSeq NM_007294.3) c.68_69del (formerly described as
c.del185AG) (p.Glu23Valfs*17), an Ashkenazi founder
mutation.24 His pedigree was not suggestive of HBOC
given that he was assigned a prior probability of 0.3% for
a BRCA1/2 mutation by the BRCAPRO algorithm25 (Fig-
ure 4A). Additionally, he did not meet NCCN guidelines
for further risk evaluation. The second participant was
heterozygous for BRCA1 c.547þ2T>A, reported as clini-
cally important in the Breast Cancer Information core
database.26 This individual had a family history of breast
and ovarian cancer and knew her mutation status before
enrolling in our study.
Three class 5 variants were identified among five partic-
ipants in BRCA2. Three participants were heterozygous
for BRCA2 (RefSeq NM_000059.3) c.5946del (formerly
described as c.6174delT) (p.Ser1982Argfs*22), an Ashke-
nazi founder mutation.24 All three of these probands re-
ported pedigrees that met NCCN guidelines for further
risk evaluation, but only one knew his mutation status
before enrolling in our study. Two other frameshift muta-
tions in BRCA2, c.5482_5486del (p.Lys1828Valfs*4) and
c.8297del (p.Thr2766Asnfs*11), which are both known
deleterious variants,27 were identified in our cohort.
Neither of the participants with these mutations met
NCCN guidelines for further risk evaluation given that
they were assigned prior probabilities of 0 and 0.6% for102 The American Journal of Human Genetics 91, 97–108, July 13, 20a BRCA1/2 mutation by the BRCAPRO algorithm25,28
(Figures 4B and 4C).
Discussion
Our goal was to pilot an analytic method to identify clini-
cally important secondary variants on a reasonable set of
genes from a large set of exome-sequence data. We focused
our analysis on 37 genes for 27 cancer-predisposing
syndromes (Table 1) well represented by LSDBs and pub-
lished data. Although this is not an exhaustive gene list,
it includes most of the well-curated cancer-susceptibility
loci and provides an appropriate starting point for this
type of analysis. This analysis has the potential to reveal
generalizable conclusions about the analytic approach
necessary for identifying such variants and the relative
frequency of clinically important variants. With respect
to the current debate surrounding secondary vari-
ants,29,30 these results provide data on the analysis and
frequency of secondary variants in a research cohort.
These data prove that medically important variants occur
at an appreciable frequency and that ignoring such vari-
ants could be detrimental to the well-being of research
participants.
The data illustrate a range of results from pathogenic to
benign. We detected a total of five class 5 variants in genes
associated with breast and ovarian cancer among seven
probands in the ClinSeq cohort. These included two
BRCA1 class 5 variants (each in a single subject) and three12
Figure 3. Characterization of 572 Variants by Pathogenicity
Class
Variants were graded from 1 to 5 with a modified version of an es-
tablished scale;18 1 is benign, and 5 is pathogenic. Variants that
failed quality filters were defined as class 0. VUSs were defined as
classes 2–4. Class 2 included variants highly likely to be benign,
class 4 included variants highly likely to be pathogenic, and others
were assigned to class 3.BRCA2 class 5 variants (one in three subjects and two in
single subjects). Our detection of these pathogenic variants
in seven probands illustrates the ability of exome
sequencing to identify secondary variants that are of
high potential medical impact; in the cases of BRCA1 and
BRCA2, the identification of these variants can substan-
tially reduce mortality in females.5,31 An important ques-
tion to ask is whether the research participants with these
variants should, or could, have been readily identified or
diagnosed by other means. Of those with BRCA1 and
BRCA2 variants, four probands reported family histories
that met NCCN guidelines for further risk assessment for
hereditary breast and ovarian cancer; three did not. Of
the four probands who met NCCN guidelines, two had
already undergone testing for BRCA1 and BRCA2. The
other two individuals, both males, had not done so at
the time of enrollment and might not have done so
outside of this study (Table 3). The fact that three (one
with a BRCA1 mutation and two with BRCA2 mutations)
out of seven probands with these high-penetrance muta-
tions were not predicted by standard approaches high-
lights the limitations of a family-history-based approach
to the detection of hereditary cancer risk. Familial risk
assessment of breast- and ovarian-cancer-susceptibility
syndromes can be limited by small family size or a paucity
of females.32 Population-based series have shown that
about half of BRCA1 and BRCA2 heterozygotes with inci-
dent cancers lack a family history of breast or ovarian
cancer.33
An additional class 5 variant was the SDHC variant
c.43C>T (p.Arg15*). Mutations in SDHC typically cause
benign, unifocal paragangliomas, which might cause cra-
nial nerve damage leading to considerable morbidity.34,35
The c.43C>T variant has been detected in the probands
of several studies, including one report with no individual
clinical data,36 one report of a patient with paragangliomaThe Aand a gastrointestinal stromal tumor and an unknown
family history,37 and one report of a patient with a glomus
tumor but no family data.38 No symptoms of this disorder
were reported by the subjects upon enrollment in these
studies, and the family history did not identify any
affected individuals. Clinical evaluation of this research
subject is underway.
In addition to these class 5 variants in BRCA1, BRCA2,
and SDHC, we classified two variants in MUTYH
(RefSeq NM_001048171.1) as class 5. These two variants,
c.494A>G (p.Tyr165Cys) and c.1145G>A (p.Gly382Asp),
are present in the general population at a combined
frequency of approximately 0.8% and account for the
majority of mutations in MUTYH (dbSNP). One of these
variants was detected in two subjects, and the other was
detected in five subjects. MUTYH mutations cause high-
penetrance colon-cancer susceptibility inherited in an
autosomal-recessive pattern. Pathogenic variants in this
gene might modestly increase the risk of colon cancer in
a heterozygous state. Because none of the variants were
found in the biallelic state, we elected to treat these vari-
ants as autosomal-recessive carrier variants.
We classified two variants as class 4 pathogenicity. Both
of these variants were in MUTYH and will be handled
similarly to the MUTYH variants described above.
We found a total of 293 class 3 and 28 class 2 variants.
One example of a class 3 variant for which the literature
review and analysis of our data led to the downgrading
of its pathogenicity is a variant in CDH1 (MIM 192090),
c.892G>A (RefSeq NM_004360.3) (p.Ala298Thr), in two
unrelated ClinSeq probands with negative family histories.
Pathogenic CDH1 mutations cause hereditary diffuse
gastric cancer (MIM 137215), which is rare and highly
penetrant.39 The c. 892A>G (p.Ala298Thr) variant was re-
ported in a single family,40 and in vitro studies showed
abnormal results in a functional assay.40,41 On the basis
of these data, the CDH1 variant was listed as causative in
HGMD; however, our identification of two probands
(2/572) with this variant and without a family history of
gastric or breast cancer (a representative family is shown
in Figure 4D) argues against this variant causing a highly
penetrant cancer syndrome. We conclude that this variant
is of unknown pathogenicity, and we therefore defined it
as class 3. Clarifying its pathogenicity will require further
research. Additional efforts to clarify pathogenicity would
be impractical for all class 3 and class 2 variants. As noted
above, the prior probability of disease in a group that is
unselected for these phenotypes is small. These data
suggest that exome interrogation for these 27 genes in
a population not ascertained for cancer generates many
more class 2 or 3 variants (n ¼ 321) than class 4 or 5
variants (n ¼ 10). This burden of ambiguous variants is
a significant issue and should be considered by clinicians,
researchers, and IRBs when designing WES studies.
Our experience is emblematic of challenges in interpret-
ing high-throughput data. HGMD and many LSDBs have
limited curation resources and significant misclassificationmerican Journal of Human Genetics 91, 97–108, July 13, 2012 103
Table 3. Participant Information for Pathogenic Variants Identified in BRCA1 and BRCA2
Gene
Mutations and RefSeq
Accession Numbers Sex Age Ethnicity
Mutation
Results
Prior to
Study
BRCAPRO
Score
Met
NCCN
Guidelines
Met USPSTF
Referral Criteria
(Women Only)
BRCA1 c.547þ2T>Aa (NM_007294.3) female 48 years northern European yes N/A yes yes
BRCA1 c.68_69del
(p.Glu23Valfs*17) (NM_007294.3)
male 61 years Ashkenazi Jewish no 0.3% no N/A
BRCA2 c.5482_5486 del
(p.Lys1828Valfs*4) (NM_000059.3)
female 56 years Japanese no 0.0% no no
BRCA2 c.5946del
(p.Ser1982Argfs*22) (NM_000059.3)
male 57 years Ashkenazi Jewish no 0.9% yes N/A
BRCA2 c.5946del
(p.Ser1982Argfs*22) (NM_000059.3)
male 60 years Ashkenazi Jewish no 42.3% yes N/A
BRCA2 c.5946del
(p.Ser1982Argfs*22) (NM_000059.3)
male 55 years Ashkenazi Jewish yes N/A yes N/A
BRCA2 c.8297del
(p.Thr2766Asnfs*11) (NM_000059.3)
male 59 years Irish no 0.6% no N/A
The following abbreviations are used: NCCN, National Comprehensive Cancer Network; and USPSTF, U.S. Preventive Services Task Force.
aThe predicted protein alteration is not provided for this splice-site mutation.rates.4,42 In addition, the pathogenicity determination of
variants can vary among LSDBs and HGMD, making inter-
pretation of these data challenging. Of the 451 variants
identified in this study, nine that were identified as
pathogenic in HGMD were reclassified as benign on the
basis of frequency in controls. Fifty-nine other variants
identified as pathogenic in HGMD were assigned patho-
genicity scores between 2 and 4 on the basis of co-occur-
rence with known pathogenic mutations, limited infor-
mation on causality, or association to a disease other
than a high-penetrance cancer syndrome. Two variants
(c.1145G>A [p.Gly382Asp] and c.494A>G [p.Tyr165Cys]
in MUTYH) assessed here as class 5 were identified in
HGMD as disease-associated polymorphisms rather
than disease-causing mutations possibly on the basis of
their high allele frequency in the general population.
Both of these variants were also included in dbSNP as
rs36053993 and rs34612342. dbSNP includes both patho-
genic and nonpathogenic variants. We observed that the
pathogenicity determination of a given variant was gener-
ally more conservative in LSDBs than in HGMD. Of the
nine variants previously classified as pathogenic in an
LSDB, we assigned eight of those nine variants pathoge-
nicity scores of 5. Furthermore, no variant that was not
identified as pathogenic in the corresponding LSDB was
assigned a pathogenicity score of 5. The 1000 Genomes
dataset3 does not include phenotypic data, so deriving
conclusions of causation from those data is difficult. These
complexities of determining causality are not novel and
have bedeviled single-gene testing laboratories for years.
However, the scale of WES greatly magnifies these issues
and argues for increased efforts to improve mutation data-
bases before genomic screening of healthy individuals
moves into the clinical realm. Cohorts such as ClinSeq,
which have robust phenotypic data and the ability to104 The American Journal of Human Genetics 91, 97–108, July 13, 20perform iterative clinical research, should be useful for
the assessment of the pathogenicity of variants and the
improvement of these databases.
We detected eight cases of a high-penetrance autosomal-
dominant tumor or cancer syndrome among 572 persons
undergoing WES. The high rate of breast and ovarian
cancer susceptibility is attributable in part to the large
proportion (~17%) of Ashkenazi Jewish participants in
ClinSeq and the 2.5% prevalence of BRCA1 or BRCA2
founder mutations among that group. However, three
participants with BRCA1 or BRCA2 mutations were not of
Ashkenazi Jewish heritage, and two of these individuals
did not meet NCCN guidelines for further risk assessment.
Additionally, the individual with the SDHC mutation did
not have a family history of paraganglioma. In all, at least
three of the seven individuals with class 5 variants had no
indication from family history that they were at an
increased risk of developing familial cancer.
This study has a number of limitations. Like the early
adopters of genetic testing in specialty clinics or those
undergoing direct-to-consumer genetic testing, ClinSeq
subjects are not representative of the general population.
The cohort has a high average income and educational
level and exhibits a high degree of curiosity and motiva-
tion regarding genetic testing and research.43 Another
potential source of bias is that some ClinSeq participants
enrolled on the basis of family history. This effect is
evident in at least one other rare disease in the ClinSeq
cohort (Biesecker et al., unpublished data). It should not
be concluded that the overall prevalence of pathogenic
mutations in this cohort is representative of the general
population. A further complication might be the average
age of our cohort. The average age of 58 years might cause
a reduced number of high-penetrance cancer alleles in the
sample because many of these variants cause morbidity12
Figure 4. Family Histories for Selected Variants
The pathogenicity classes ascribed to variants detected in the probands of each family are as follows: class 5 for BRCA1 and BRCA2 vari-
ants in families A, B, and C and class 3 for the CDH1 variant in family D. The diamond symbol indicates relatives of probands in some
families so that these families can remain anonymous. Of note, a first-degree relative and a second-degree relative of the proband in
family Dwere diagnosedwith prostate cancer; however, these individuals were from separate lineages, and prostate cancer is not thought
to be a part of hereditary diffuse gastric cancer syndrome.and mortality at younger ages. Although 572 exomes is a
prodigious amount of data, we cannot measure clinical
utility. We do not have cost-effectiveness data because
neither the sequencing costs nor the costs of the down-
stream medical evaluations can be readily measured. We
did not measure the resources required to annotate these
exomes, but we estimate that analyzing these 37 genes
required 1–2 hours of time per sample. This time require-The Ament is falling as our experience accumulates. We can
now analyze additional exomes in less than 1 hr. Irrespec-
tive of this downward trend, scaling this manual curation
approach to the entire genome is impractical, and these
data highlight the urgent need for improved analytic algo-
rithms andmutation databases for the automation of these
processes. To address this issue, we submitted a description
of our study and interpretations to ClinVar. The ClinVarmerican Journal of Human Genetics 91, 97–108, July 13, 2012 105
infrastructure and accessioning of submitted data is de-
signed to facilitate curation of variants at multiple levels
(e.g., uncurated, single-source curation, expert-level cura-
tion, or practice guidelines). The goal of this resource is
to provide a freely available archive of reported human
variation and the evidence used for the generation of the
interpretation of that variation with the viewpoint of
providing infrastructure for future reinterpretation.
Overall, the data argue for the potential medical utility
of the interpretation and return of secondary variants
because the number of identified individuals with clini-
cally important results is substantial. In addition, these
data suggest that it might be possible to implement a clin-
ical screen for rare cancer-susceptibility syndromes with
the use of WES data and that cases that would otherwise
go undiagnosed until family members manifest cancer
might be detected with a genomics-first approach. Genetic
testing for cancer susceptibility identified by an atypical
disease in the proband and/or by positive family history
has been widely embraced, suggesting that oncology
might be one of the earliest specialties to benefit from
genomic screening. Studies of other highly penetrant, clin-
ically important, adult-onset disorders will help clarify the
potential utility of screening with the use of genomics.
Further work is needed for the expansion of these efforts
into larger, more varied cohorts, the expansion of the
gene target list, the automation of these processes, and
the determination of their efficacy.Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.cell.com/AJHG.Acknowledgments
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